New technologies for influenza vaccines (Q30411859)

21 June 2017

title

New technologies for influenza vaccines (English)

1 reference

21 June 2017

1 reference

1

Philip R Dormitzer

1 reference

21 June 2017

Theodore F Tsai

2

1 reference

21 June 2017

Giuseppe Del Giudice

series ordinal

3

1 reference

21 June 2017

publication date

1 January 2012

1 reference

Human Vaccines & Immunotherapeutics

21 June 2017

published in

1 reference

21 June 2017

volume

8

1 reference

21 June 2017

issue

1

1 reference

21 June 2017

page(s)

45-58

1 reference

THE ANTIBODY RESPONSE OF HUMAN SUBJECTS VACCINATED WITH THE VIRUS OF HUMAN INFLUENZA.

21 June 2017

cites work

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18859

Safety and immunogenicity of a novel influenza subunit vaccine produced in mammalian cell culture.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18859

Dose ranging of adjuvant and antigen in a cell culture H5N1 influenza vaccine: safety and immunogenicity of a phase 1/2 clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18859

A clinical trial of a whole-virus H5N1 vaccine derived from cell culture.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18859

Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18859

Safety and immunogenicity of a trivalent, inactivated, mammalian cell culture-derived influenza vaccine in healthy adults, seniors, and children

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18859

Safety, tolerability and immunogenicity of a mammalian cell-culture-derived influenza vaccine: a sequential Phase I and Phase II clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18859

Safety and immunogenicity of a new influenza vaccine grown in mammalian cell culture

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18859

A cell culture (Vero)-derived H5N1 whole-virus vaccine induces cross-reactive memory responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18859

Evidence for host-cell selection of influenza virus antigenic variants

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18859

Alterations in the hemagglutinin associated with adaptation of influenza B virus to growth in eggs

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18859

Molecular changes associated with adaptation of human influenza A virus in embryonated chicken eggs

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18859

Avian flu: influenza virus receptors in the human airway

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18859

Current challenges in implementing cell-derived influenza vaccines: implications for production and regulation, July 2007, NIBSC, Potters Bar, UK.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18859

Evaluation of the safety, reactogenicity and immunogenicity of FluBlok trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy children aged 6-59 months

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18859

Immune responses of healthy subjects to a single dose of intramuscular inactivated influenza A/Vietnam/1203/2004 (H5N1) vaccine after priming with an antigenic variant.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18859

Expression and purification of an influenza hemagglutinin--one step closer to a recombinant protein-based influenza vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18859

The antigenic structure of the influenza virus A/PR/8/34 hemagglutinin (H1 subtype)

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18859

Comparative efficacy of neutralizing antibodies elicited by recombinant hemagglutinin proteins from avian H5N1 influenza virus

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18859

Antigenic determinants of influenza virus haemagglutinin. X. A comparison of the physical and antigenic properties of monomeric and trimeric forms.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18859

Structure of the uncleaved human H1 hemagglutinin from the extinct 1918 influenza virus

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18859

Crystal structure of the swine-origin A (H1N1)-2009 influenza A virus hemagglutinin (HA) reveals similar antigenicity to that of the 1918 pandemic virus

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18859

Immunogenicity and efficacy of flagellin-fused vaccine candidates targeting 2009 pandemic H1N1 influenza in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18859

Efficacious recombinant influenza vaccines produced by high yield bacterial expression: a solution to global pandemic and seasonal needs.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18859

Properly folded bacterially expressed H1N1 hemagglutinin globular head and ectodomain vaccines protect ferrets against H1N1 pandemic influenza virus

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18859

Induction of a potent immune response in the elderly using the TLR-5 agonist, flagellin, with a recombinant hemagglutinin influenza-flagellin fusion vaccine (VAX125, STF2.HA1 SI).

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18859

Safety and immunogenicity of a recombinant hemagglutinin influenza–flagellin fusion vaccine (VAX125) in healthy young adults

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18859

Influenza virus-like particles comprised of the HA, NA, and M1 proteins of H9N2 influenza virus induce protective immune responses in BALB/c mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18859

Influenza virus-like particles produced by transient expression in Nicotiana benthamiana induce a protective immune response against a lethal viral challenge in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18859

Cross-clade protective immune responses to influenza viruses with H5N1 HA and NA elicited by an influenza virus-like particle

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18859

H5N1 virus-like particle vaccine elicits cross-reactive neutralizing antibodies that preferentially bind to the oligomeric form of influenza virus hemagglutinin in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18859

Safety and immunogenicity of a virus-like particle pandemic influenza A (H1N1) 2009 vaccine in a blinded, randomized, placebo-controlled trial of adults in Mexico

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18859

Preclinical and clinical development of plant-made virus-like particle vaccine against avian H5N1 influenza

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18859

Current status of live attenuated influenza vaccine in the United States for seasonal and pandemic influenza.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18859

The relative efficacy of trivalent live attenuated and inactivated influenza vaccines in children and adults

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18859

Systematic review of worldwide variations of the prevalence of wheezing symptoms in children

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18859

Comparative efficacy of inactivated and live attenuated influenza vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18859

Prevention of symptomatic seasonal influenza in 2005-2006 by inactivated and live attenuated vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18859

A novel type of influenza vaccine: safety and immunogenicity of replication-deficient influenza virus created by deletion of the interferon antagonist NS1.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18859

Live attenuated influenza viruses containing NS1 truncations as vaccine candidates against H5N1 highly pathogenic avian influenza

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18859

NS-based live attenuated H1N1 pandemic vaccines protect mice and ferrets

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18859

Structure-based design of NS2 mutants for attenuated influenza A virus vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18859

Recombinant vectors as influenza vaccines.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18859

Adenovirus as a carrier for the development of influenza virus-free avian influenza vaccines.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18859

Adenovirus-vectored drug-vaccine duo as a rapid-response tool for conferring seamless protection against influenza

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18859

Safety and immunogenicity of adenovirus-vectored nasal and epicutaneous influenza vaccines in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18859

Candidate influenza vaccines based on recombinant modified vaccinia virus Ankara.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18859

Creation of a bacterial cell controlled by a chemically synthesized genome

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18859

Optimizing the baculovirus expression vector system

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18859

The evolutionary dynamics of human influenza B virus

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18859

The need for quadrivalent vaccine against seasonal influenza

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18859

Protective efficacy of live-attenuated influenza vaccine (multivalent, Ann Arbor strain): a literature review addressing interference

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18859

Relative merits of aqueous and adjuvant influenza vaccines when used in a two-dose schedule

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18859

MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18859

Vaccines with the MF59 adjuvant do not stimulate antibody responses against squalene

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18859

An MF59-adjuvanted inactivated influenza vaccine containing A/Panama/1999 (H3N2) induced broader serological protection against heterovariant influenza virus strain A/Fujian/2002 than a subunit and a split influenza vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18859

Cross-protection by MF59-adjuvanted influenza vaccine: neutralizing and haemagglutination-inhibiting antibody activity against A(H3N2) drifted influenza viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18859

Cross-reactive antibodies in middle-aged and elderly volunteers after MF59-adjuvanted subunit trivalent influenza vaccine against B viruses of the B/Victoria or B/Yamagata lineages

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18859

MF59-adjuvanted vaccine: a safe and useful tool to enhance and broaden protection against seasonal influenza viruses in subjects at risk

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18859

Antibody response against heterogeneous circulating influenza virus strains elicited by MF59- and non-adjuvanted vaccines during seasons with good or partial matching between vaccine strain and clinical isolates.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18859

Immunogenicity of three different influenza vaccines against homologous and heterologous strains in nursing home elderly residents

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18859

The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18859

Effectiveness of MF59-adjuvanted subunit influenza vaccine in preventing hospitalisations for cardiovascular disease, cerebrovascular disease and pneumonia in the elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18859

Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18859

MF59-adjuvanted H5N1 vaccine induces immunologic memory and heterotypic antibody responses in non-elderly and elderly adults

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18859

Impact of prior or concomitant seasonal influenza vaccination on MF59-adjuvanted H1N1v vaccine (Focetria) in adult and elderly subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18859

Antigenically distinct MF59-adjuvanted vaccine to boost immunity to H5N1.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18859

Fast rise of broadly cross-reactive antibodies after boosting long-lived human memory B cells primed by an MF59 adjuvanted prepandemic vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18859

Enhanced immunogenicity of seasonal influenza vaccines in young children using MF59 adjuvant

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18859

Emulsion-based adjuvants for influenza vaccines.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18859

Adjuvant System AS03 containing α-tocopherol modulates innate immune response and leads to improved adaptive immunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18859

Current status and progress of prepandemic and pandemic influenza vaccine development.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18859

Immunogenicity and safety of a two-dose schedule of whole-virion and AS03A-adjuvanted 2009 influenza A (H1N1) vaccines: a randomised, multicentre, age-stratified, head-to-head trial

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18859

H1N1 vaccines in a large observational cohort of patients with inflammatory bowel disease treated with immunomodulators and biological therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18859

Explorations of clinical trials and pharmacovigilance databases of MF59®-adjuvanted influenza vaccines for associated cases of narcolepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18859

An adjuvanted, low-dose, pandemic influenza A (H5N1) vaccine candidate is safe, immunogenic, and induces cross-reactive immune responses in healthy adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18859

Human innate immunosenescence: causes and consequences for immunity in old age.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18859

Clinical implications of aging skin: cutaneous disorders in the elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18859

The Immunizing Effect of Influenza A/New Jersey/76 (Hsw1N1) Virus Vaccine Administered Intradermally and Intramuscularly to Adults

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18859

Comparison of Responses to Influenza A/New Jersey /76-A/Victoria/75 Virus Vaccine Administered Intradermally or Subcutaneously to Adults with Chronic Respiratory Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18859

Antibody responses after dose-sparing intradermal influenza vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18859

Seasonal influenza vaccine delivered by intradermal microinjection: A randomised controlled safety and immunogenicity trial in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18859

Intradermal influenza vaccination of healthy adults using a new microinjection system: a 3-year randomised controlled safety and immunogenicity trial

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18859

Safety and efficacy of a novel microneedle device for dose sparing intradermal influenza vaccination in healthy adults

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18859

Intradermal influenza vaccination in immunocompromized patients is immunogenic and feasible

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18859

Comparative immunogenicity of trivalent influenza vaccine administered by intradermal or intramuscular route in healthy adults

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18859

Evaluation of a single dose of half strength inactivated influenza vaccine in healthy adults

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18859

Half- vs full-dose trivalent inactivated influenza vaccine (2004-2005): age, dose, and sex effects on immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18859

Intradermal influenza vaccine administered using a new microinjection system produces superior immunogenicity in elderly adults: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18859

Evaluation of non-inferiority of intradermal versus adjuvanted seasonal influenza vaccine using two serological techniques: a randomised comparative study

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18859

Intradermal influenza vaccine and new devices: a promising chance for vaccine improvement

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18859

Comparison of the immunogenicity and safety of a split-virion, inactivated, trivalent influenza vaccine (Fluzone®) administered by intradermal and intramuscular route in healthy adults

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18859

A phase I evaluation of inactivated influenza A/H5N1 vaccine administered by the intradermal or the intramuscular route

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18859

Microneedle vaccination with stabilized recombinant influenza virus hemagglutinin induces improved protective immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18859

Dissolving polymer microneedle patches for influenza vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18859

Transcutaneous immunization with heat-labile enterotoxin: development of a needle-free vaccine patch

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18859

Use of a patch containing heat-labile toxin from Escherichia coli against travellers' diarrhoea: a phase II, randomised, double-blind, placebo-controlled field trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18859

Immunostimulant patch enhances immune responses to influenza virus vaccine in aged mice

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18859

Phase I evaluation of intranasal trivalent inactivated influenza vaccine with nontoxigenic Escherichia coli enterotoxin and novel biovector as mucosal adjuvants, using adult volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18859

Pathogenesis of Influenza A/H5N1 virus infection in ferrets differs between intranasal and intratracheal routes of inoculation

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18859

Transient facial nerve paralysis (Bell's palsy) following intranasal delivery of a genetically detoxified mutant of Escherichia coli heat labile toxin

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18859

Needle-free influenza vaccination.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18859

HPLC-based quantification of haemagglutinin in the production of egg- and MDCK cell-derived influenza virus seasonal and pandemic vaccines.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18859

Optimization and qualification of a quantitative reversed-phase HPLC method for hemagglutinin in influenza preparations and its comparative evaluation with biochemical assays

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18859

Quantification of influenza virus hemagglutinins in complex mixtures using isotope dilution tandem mass spectrometry.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18859

A simple slot blot for the detection of virtually all subtypes of the influenza A viral hemagglutinins using universal antibodies targeting the fusion peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18859

A novel assay for influenza virus quantification using surface plasmon resonance.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18859

Detection and identification of influenza virus antigens by nylon-coupled enzyme-linked immunoassay

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18859

Avian glycan-specific IgM monoclonal antibodies for the detection and quantitation of type A and B haemagglutinins in egg-derived influenza vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18859

Vaxfectin-formulated influenza DNA vaccines encoding NP and M2 viral proteins protect mice against lethal viral challenge.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18859

Vaccination focusing immunity on conserved antigens protects mice and ferrets against virulent H1N1 and H5N1 influenza A viruses.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18859

Purified influenza virus nucleoprotein protects mice from lethal infection

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18859

Comparative efficacy of hemagglutinin, nucleoprotein, and matrix 2 protein gene-based vaccination against H5N1 influenza in mouse and ferret

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18859

The immunodominant influenza matrix T cell epitope recognized in human induces influenza protection in HLA-A2/K(b) transgenic mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18859

A universal epitope-based influenza vaccine and its efficacy against H5N1.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18859

Cross-protection against influenza virus infection by intranasal administration of M1-based vaccine with chitosan as an adjuvant

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18859

Cytotoxic T-cell immunity to influenza.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18859

T cells primed by influenza virion internal components can cooperate in the antibody response to haemagglutinin

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18859

Structure and mechanism of the M2 proton channel of influenza A virus

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18859

Structural basis for the function and inhibition of an influenza virus proton channel

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18859

An influenza A vaccine based on tetrameric ectodomain of matrix protein 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18859

Human antibodies reveal a protective epitope that is highly conserved among human and nonhuman influenza A viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18859

Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18859

A universal influenza A vaccine based on the extracellular domain of the M2 protein

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18859

Vaccination of pigs with a DNA construct expressing an influenza virus M2-nucleoprotein fusion protein exacerbates disease after challenge with influenza A virus

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18859

Safety and immunogenicity of a recombinant M2e-flagellin influenza vaccine (STF2.4xM2e) in healthy adults

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18859

Broadly neutralizing human antibody that recognizes the receptor-binding pocket of influenza virus hemagglutinin

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18859

Cross-protective potential of a novel monoclonal antibody directed against antigenic site B of the hemagglutinin of influenza A viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18859

Antibody recognition of a highly conserved influenza virus epitope

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18859

A highly conserved neutralizing epitope on group 2 influenza A viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18859

Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18859

A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18859

Pre- and postexposure use of human monoclonal antibody against H5N1 and H1N1 influenza virus in mice: viable alternative to oseltamivir

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18859

Rational design of vaccines to elicit broadly neutralizing antibodies to HIV-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18859

Induction of broadly neutralizing H1N1 influenza antibodies by vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18859

Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18859

Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18859

Antibody responses to natural influenza A/H1N1/09 disease or following immunization with adjuvanted vaccines, in immunocompetent and immunocompromised children

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18859

Structural identification of the antibody-binding sites of Hong Kong influenza haemagglutinin and their involvement in antigenic variation

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FHV.8.1.18859

21 January 2018

Identifiers

DOI

10.4161/HV.8.1.18859

1 reference

21 June 2017

1 reference